Stem cells in bone diseases: Current clinical practice

British Medical Bulletin

Volumn 99, Issue 1, 2011, Pages 199-210

  Beyth, Shaul ^a   Schroeder, Josh ^a   Liebergall, Meir ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Bone; Fracture non union; Infantile hypophosphatasia; Mesenchymal stem cells; Osteogenesis imperfecta; Stem cells

Indexed keywords

HYDROXYAPATITE; RECOMBINANT PARATHYROID HORMONE;

ARTICLE; BONE DISEASE; CELL FUNCTION; CLINICAL PRACTICE; FRACTURE HEALING; FRACTURE NONUNION; HUMAN; HYPOPHOSPHATASIA; IMMUNOMODULATION; MESENCHYMAL STEM CELL; NONHUMAN; OSTEOGENESIS IMPERFECTA; PRIORITY JOURNAL; STEM CELL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

BONE AND BONES; BONE DISEASES; BONE REGENERATION; FRACTURE HEALING; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; OSTEOGENESIS; REGENERATIVE MEDICINE; STEM CELL RESEARCH;

EID: 80052700496     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldr035     Document Type: Article

References (53)

1. Meyer RA Jr, Tsahakis PJ, Martin DF et al. Age and ovariectomy impair both the normalization of mechanical properties and the accretion of mineral by the fracture callus in rats. J Orthop Res 2001;19:428-35. (Pubitemid 32472013)
2. Khosla S, Westendorf JJ, Modder UI. Concise review: insights from normal bone remodeling and stem cell-based therapies for bone repair. Stem Cells 2010;28:2124-8.
3. Gardner MJ, Putnam SM, Wong A et al. Differential fracture healing resulting from fixation stiffness variability: a mouse model. J Orthop Sci 2011;16:298-303.
4. Kasturi G, Adler RA. Mechanical means to improve bone strength: ultrasound and vibration. Curr Rheumatol Rep 13:251-6.
5. Caplan AI. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 2007;213:341-7. (Pubitemid 47509711)
6. Connolly JF, Guse R, Tiedeman J et al. Autologous marrow injection for delayed unions of the tibia: a preliminary report. J Orthop Trauma 1989;3:276-82.
7. Caplan AI. Bioactive factors in bone: Marshall R. Urist, M.D. May 1988 Kerrville, Texas. Connect Tissue Res 1989;23:103-6.
8. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-7. (Pubitemid 29282067)
9. Caplan AI. Mesenchymal stem cells. J Orthop Res 1991;9:641-50.
10. Bianco P, Robey PG, Saggio I et al. 'Mesenchymal' stem cells in human bone marrow (skeletal stem cells): a critical discussion of their nature, identity, and significance in incurable skeletal disease. Hum Gene Ther 2010;21:1057-66.
11. Zaidi N, Nixon AJ. Stem cell therapy in bone repair and regeneration. Ann N Y Acad Sci 2007;1117:62-72. (Pubitemid 350191290)
12. Pitchford SC, Furze RC, Jones CP et al. Differential mobilization of subsets of progenitor cells from the bone marrow. Cell Stem Cell 2009;4:62-72.
13. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature 1981;292:154-6. (Pubitemid 11050741)
14. Hematti P. Human embryonic stem cell-derived mesenchymal progenitors: an overview. Methods Mol Biol 2011;690:163-74.
15. Chanda D, Kumar S, Ponnazhagan S. Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in diseases of the skeleton. J Cell Biochem 2010;111:249-57.
16. Sensebe L, Krampera M, Schrezenmeier H et al. Mesenchymal stem cells for clinical application. Vox Sang 2010;98:93-107.
17. Undale AH, Westendorf JJ, Yaszemski MJ et al. Mesenchymal stem cells for bone repair and metabolic bone diseases. Mayo Clin Proc 2009;84:893-902.
18. Arthur A, Zannettino A, Gronthos S. The therapeutic applications of multipotential mesenchymal/stromal stem cells in skeletal tissue repair. J Cell Physiol 2009;218:237-45.
19. Augello A, Kurth TB, De Bari C. Mesenchymal stem cells: a perspective from in vitro cultures to in vivo migration and niches. Eur Cell Mater 2010;20:121-33.
20. Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315-7. (Pubitemid 44269669)
21. da Silva Meirelles L, Caplan AI, Nardi NB. In search of the in vivo identity of mesenchymal stem cells. Stem Cells 2008;26:2287-99.
22. Granero-Molto F, Weis JA, Longobardi L et al. Role of mesenchymal stem cells in regenerative medicine: application to bone and cartilage repair. Expert Opin Biol Ther 2008;8:255-68. (Pubitemid 351428415)
23. De Bari C, Dell'Accio F, Karystinou A et al. A biomarker-based mathematical model to predict bone-forming potency of human synovial and periosteal mesenchymal stem cells. Arthritis Rheum 2008;58:240-50.
24. Crisan M, Yap S, Casteilla L et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008;3:301-13.
25. Tondreau T, Meuleman N, Delforge A et al. Mesenchymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood: proliferation, Oct4 expression, and plasticity. Stem Cells 2005;23:1105-12. (Pubitemid 41377726)
26. Ruster B, Gottig S, Ludwig RJ et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 2006;108:3938-44. (Pubitemid 44864580)
27. Caplan AI. Why are MSCs therapeutic? New data: new insight. J Pathol 2009;217:318-24.
28. De Bari C, Kurth TB, Augello A. Mesenchymal stem cells from development to postnatal joint homeostasis, aging, and disease. Birth Defects Res C Embryo Today 2010;90:257-71.
29. Gago N, Perez-Lopez V, Sanz-Jaka JP et al. Age-dependent depletion of human skin-derived progenitor cells. Stem Cells 2009;27:1164-72.
30. Stolzing A, Jones E, McGonagle D et al. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev 2008;129:163-73.
31. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:1815-22. (Pubitemid 40223708)
32. Bartholomew A, Sturgeon C, Siatskas M et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002;30:42-8. (Pubitemid 34059216)
33. Beyth S, Borovsky Z, Mevorach D et al. Human mesenchymal stem cells alter antigenpresenting cell maturation and induce T-cell unresponsiveness. Blood 2005;105:2214-9. (Pubitemid 40731815)
34. Yagi H, Soto-Gutierrez A, Parekkadan B et al. Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplant 19:667-79.
35. Tse WT, Pendleton JD, Beyer WM et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003;75:389-97. (Pubitemid 36222968)
36. Biron CA. Activation and function of natural killer cell responses during viral infections. Curr Opin Immunol 1997;9:24-34. (Pubitemid 27098860)
37. Bouffi C, Bony C, Courties G et al. IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One 5:e14247.
38. Nemeth K, Keane-Myers A, Brown JM et al. Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc Natl Acad Sci USA 107:5652-7.
39. Birnbaum T, Roider J, Schankin CJ et al. Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. J Neurooncol 2007;83:241-7. (Pubitemid 46952234)
40. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008;8:726-36.
41. Le Blanc K, Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008;371:1579-86. (Pubitemid 351626841)
42. Ringden O, Uzunel M, Rasmusson I et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006;81:1390-7. (Pubitemid 43847148)
43. Bianco P. Back to the future: moving beyond mesenchymal stem cells. J Cell Biochem 112:1713-21.
44. Hernigou P, Poignard A, Beaujean F et al. Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells. J Bone Joint Surg Am 2005;87:1430-7. (Pubitemid 40917741)
45. Quarto R, Mastrogiacomo M, Cancedda R et al. Repair of large bone defects with the use of autologous bone marrow stromal cells. N Engl J Med 2001;344:385-6. (Pubitemid 32107654)
46. Marcacci M, Kon E, Moukhachev V et al. Stem cells associated with macroporous bioceramics for long bone repair: 6- to 7-year outcome of a pilot clinical study. Tissue Eng 2007;13:947-55. (Pubitemid 46870419)
47. Chatterjea A, Meijer G, van Blitterswijk C et al. Clinical application of human mesenchymal stromal cells for bone tissue engineering. Stem Cells Int 2010;11:215625.
48. Horwitz EM, Prockop DJ, Fitzpatrick LA et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999;5:309-13. (Pubitemid 29124367)
49. Horwitz EM, Prockop DJ, Gordon PL et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 2001;97:1227-31. (Pubitemid 32183743)
50. Horwitz EM, Gordon PL, Koo WK et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA 2002;99:8932-7. (Pubitemid 34693661)
51. Le Blanc K, Gotherstrom C, Ringden O et al. Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation 2005;79:1607-14. (Pubitemid 40847594)
52. Whyte MP, Kurtzberg J, McAlister WH et al. Marrow cell transplantation for infantile hypophosphatasia. J Bone Miner Res 2003;18:624-36. (Pubitemid 36899312)
53. Cahill RA, Wenkert D, Perlman SA et al. Infantile hypophosphatasia: transplantation therapy trial using bone fragments and cultured osteoblasts. J Clin Endocrinol Metab 2007;92:2923-30. (Pubitemid 47236351)